Leslie Baitinger

Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: A randomized, double-blind, placebo-controlled trial

Mani S. Kavuru, Julian Melamed, Gary N. Gross et al. · Journal of Allergy and Clinical Immunology · 2000 · 240 citations · Full text

Asthma, Allergy Medicine, Medicine +6

Combined Salmeterol 50 μ g and Fluticasone Propionate 250 μ g in the Diskus Device for the Treatment of Asthma

Gail Shapiro, William R. Lumry, James Wolfe et al. · American Journal of Respiratory and Critical Care Medicine · 2000 · 201 citations

Salmeterol response is not affected by β2-adrenergic receptor genotype in subjects with persistent asthma

Eugene R. Bleecker, Steve Yancey, Leslie Baitinger et al. · Journal of Allergy and Clinical Immunology · 2006 · 154 citations · Full text

Asthma, Inflammatory Lung Disease, Medicine +6

Efficacy and Safety of Fluticasone Propionate/Salmeterol HFA 134A MDI in Patients with Mild‐to‐Moderate Persistent Asthma

David S. Pearlman, David B. Peden, John J. Condemi et al. · Journal of Asthma · 2004 · 50 citations

Asthma, Allergy, Inflammatory Lung Disease +14

Fluticasone propionate and salmeterol administered via Diskus compared with salmeterol or fluticasone propionate alone in patients suboptimally controlled with short-acting β2-agonists

John Murray, Richard R. Rosenthal, Laura L. Somerville et al. · Annals of Allergy Asthma & Immunology · 2004 · 39 citations

Short-acting β2-Agonists, Clinical Therapeutic, Medicine +6